In 2022, Chr. Hansen’s purchases from […] Manufacturers amounted to a total of
about EUR [information on Chr. Hansen’s purchases from manufacturers].
Chr. Hansen only purchased EUR [information on Chr. Hansen’s purchases from 277 Form CO. para. 1500. 278 Form CO. para. 1501. 279 To estimate the share of the market those customers represent, the Parties explain that less than 10% of the lactase sold globally and in the EEA goes into organic production (Form CO. para. 673 and 674). Another manufacturer estimates that customers bound to use non-GM produced lactase represent 25% of the market (Minutes of a call with a manufacturer, 10 October 2023, para. 12). 280 Margins earned vary from the year to year and depending on whether sales are made direct to customers or via distributors. In any case Novozymes [information on margins]. Novozymes earns a gross margin between [margin]% and [margin]% on the sales of Saphera®, while its gross margin on the sale of Lactozym® Pure is between [margin]% and [margin]% (PN RFI 5, response to question 30). 281 Form CO. para. 1000 and as also seen in switching data in para 1003 et seq. 282 PN RFI 5, response to question 26. 283 Chr. Hansen earned in 2022 a gross margin of [margin]% on its sales of Ha-Lactase™ and NOLA® Fit (PN RFI 5, response to question 30). 284 Novozymes currently earns a gross margin of approx. [margin]% on its sales of lactase to [information on customers] (Form CO. para. 1511). 285 [Information on suppliers]. 286 In 2022, Chr. Hansen purchased [information on Chr. Hansen's purchases from suppliers] (Form CO. tables 72 and 73). manufacturers].
287 Consequently, Chr. Hansen explains that it is [information on Chr. Hansen’s purchases from manufacturers], 288.289